This is a routine pipeline update with no hard data or catalysts. Monitor upcoming data readouts from CARTITUDE-5/6 and the new IND-cleared programs for potential catalysts. No immediate trading action warranted.
Price Chart
Executive Summary
Legend Biotech filed a 6-K on September 14, 2026, making an updated clinical pipeline available on its website. The pipeline shows progress across autologous, allogeneic, and in vivo cell therapy programs, including CARVYKTI follow-up in frontline multiple myeloma and new IND-cleared programs in solid tumors and autoimmune diseases. This is a routine pipeline update with no financial data or material new catalysts disclosed.
Key Facts
- Legend Biotech updated its clinical pipeline via a 6-K filing on September 14, 2026.
- CARVYKTI (BCMA-directed) continues patient follow-up in frontline NDMM trials CARTITUDE-5 and CARTITUDE-6, and is enrolling in CARTITUDE-10.
- Autologous therapy LB1908 (Claudin 18.2) met its primary endpoint in relapsed/refractory gastric and pancreatic cancers.
- Novartis-partnered LB2102 (DLL3) met its primary endpoint in 2L+ small cell lung cancer and large cell neuroendocrine carcinoma.
- Multiple allogeneic and in vivo programs are enrolling or initiating in autoimmune diseases, B-cell NHL, and multiple myeloma.
- No financial results, guidance, or material agreements were disclosed in this filing.
Financial Impact
No financial figures disclosed in this filing.
Risk Factors
- No new clinical data or regulatory milestones were announced, limiting near-term catalysts.
- Competitive landscape in multiple myeloma cell therapy remains intense with multiple BCMA and GPRC5D programs.
- Allogeneic and in vivo programs are early-stage with no established safety/efficacy data.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-006027 |
| Exhibit: exh_991.htm | 0001171843-26-006027 |
| Document: 0001171843-26-006027-index-headers.html | 0001171843-26-006027 |
| Document: 0001171843-26-006027-index.html | 0001171843-26-006027 |
| Document: 0001171843-26-006027.txt | 0001171843-26-006027 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | 6-K | $19.80 | awaiting T+20 | — | $20.39 (+2.98%) |
Oct 13, 2026 13d ago | 6-K | $17.88 | awaiting T+20 | — | $20.39 (+14.04%) |
Sep 29, 2026 27d ago | 144 | $18.82 | awaiting T+20 | — | $20.39 (+8.34%) |
Sep 25, 2026 4w ago | 6-K | $19.11 $19.27 | ▲ +0.84% | ▲ +2.31% | $20.39 (+6.70%) |
Sep 25, 2026 4w ago | Press Release | $19.11 $19.27 | ▲ +0.84% | ▲ +2.31% | $20.39 (+6.70%) |
Sep 15, 2026 5w ago | 6-K | $17.67 $17.88 | ▲ +1.19% | ▼ −1.53% | $20.39 (+15.39%) |
Sep 14, 2026 6w ago | 6-K | $18.53 $17.80 | ▼ −3.94% | ▼ −6.20% | $20.39 (+10.04%) |
Aug 11, 2026 10w ago | 6-K | $21.83 $19.91 | ▼ −8.80% | ▼ −7.74% | $20.39 (−6.60%) |
Jul 27, 2026 13w ago | 6-K | $19.27 $20.94 | ▼ −8.67% | ▼ −5.37% | $20.39 (−5.81%) |
Jul 27, 2026 13w ago | Press Release | $19.27 $20.94 | ▲ +8.67% | ▲ +5.37% | $20.39 (+5.81%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers